{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:30:02Z","timestamp":1782747002261,"version":"3.54.5"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T12:13:51Z","timestamp":1614946431000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Diagnosis and management of adult T-cell leukemia\/lymphoma"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-497X","authenticated-orcid":false,"given":"Kenji","family":"Ishitsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.005_bib0001","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0002","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.005_bib0003","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"39","key":"10.1053\/j.seminhematol.2021.02.005_bib0004","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s12889-016-3366-5","article-title":"Human T-Lymphotropic Virus type 1 infection in an Indigenous Australian population: epidemiological insights from a hospital-based cohort study","volume":"16","author":"Einsiedel","year":"2016","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0006","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/aid.1993.9.381","article-title":"An HTLV-I vaccine: why, how, for whom?","volume":"9","author":"de The","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0008","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.005_bib0009","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1182\/blood-2010-11-316794","article-title":"Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia\/lymphoma","volume":"117","author":"Sawada","year":"2011","journal-title":"Blood"},{"issue":"3-4","key":"10.1053\/j.seminhematol.2021.02.005_bib0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10428199309087005","article-title":"Autopsy findings in 47 cases of adult T-cell leukemia\/lymphoma in Miyazaki prefecture, Japan","volume":"11","author":"Suzumiya","year":"1993","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0011","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0012","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.005_bib0013","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2403965","article-title":"FOXP3, a selective marker for a subset of adult T-cell leukaemia\/lymphoma","volume":"19","author":"Roncador","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0014","series-title":"Adult T-Cell Leukemia","first-page":"221","article-title":"Chemotherapy of ATL","author":"Shimoyama","year":"1994"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12977-020-00534-0","article-title":"Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan","volume":"17","author":"Okuma","year":"2020","journal-title":"Retrovirology"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.005_bib0017","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.005_bib0018","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","article-title":"Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma","volume":"130","author":"Katsuya","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.005_bib0021","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/cas.13641","article-title":"Evaluation of two prognostic indices for adult T-cell leukemia\/lymphoma in the subtropical endemic area, Okinawa, Japan","volume":"109","author":"Tamaki","year":"2018","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.005_bib0022","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"issue":"34","key":"10.1053\/j.seminhematol.2021.02.005_bib0023","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0024","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.15950","article-title":"Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801","volume":"186","author":"Toyoda","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.005_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0026","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.005_bib0027","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0029","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.005_bib0031","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0032","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0033","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cncr.32556","article-title":"Epidemiology and survival trend of adult T-cell leukemia\/lymphoma in the United States","volume":"126","author":"Shah","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.005_bib0034","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","article-title":"Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States","volume":"2","author":"Malpica","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.005_bib0035","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/bloodadvances.2020001628","article-title":"Adult T-cell leukemia\/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1","volume":"4","author":"Ramassamy","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.005_bib0036","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.005_bib0037","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W","article-title":"Central nervous system involvement in adult T-cell leukemia\/lymphoma","volume":"65","author":"Teshima","year":"1990","journal-title":"Cancer"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.005_bib0038","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.005_bib0039","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.005_bib0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients","volume":"113","author":"Matutes","year":"2001","journal-title":"Br J Haematol"},{"issue":"3-4","key":"10.1053\/j.seminhematol.2021.02.005_bib0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428190109057927","article-title":"The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia\/lymphoma","volume":"40","author":"White","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.005_bib0042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol J"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0043","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1358\/dot.2011.47.8.1590785","article-title":"Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia\/lymphoma","volume":"47","author":"Ishitsuka","year":"2011","journal-title":"Drugs of today"},{"issue":"27","key":"10.1053\/j.seminhematol.2021.02.005_bib0044","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of Zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1053\/j.seminhematol.2021.02.005_bib0045","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0046","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0047","doi-asserted-by":"crossref","unstructured":"Ishida T, Jo T, Takemoto S, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2018.","DOI":"10.1111\/bjh.15123"},{"issue":"10168","key":"10.1053\/j.seminhematol.2021.02.005_bib0048","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"28","key":"10.1053\/j.seminhematol.2021.02.005_bib0049","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.005_bib0050","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.005_bib0051","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.005_bib0052","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41409-018-0139-z","article-title":"Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia\/lymphoma","volume":"53","author":"Inoue","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.005_bib0053","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V76.10.2065.2065","article-title":"Expression of P-glycoprotein in adult T-cell leukemia cells","volume":"76","author":"Kuwazuru","year":"1990","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.005_bib0054","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bbmt.2014.08.012","article-title":"Treatment of patients with adult T cell leukemia\/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey","volume":"20","author":"Kato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.005_bib0055","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"28","key":"10.1053\/j.seminhematol.2021.02.005_bib0056","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia\/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0057","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0058","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia \/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0059","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.13220","article-title":"Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma","volume":"102","author":"Ishitsuka","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.005_bib0060","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"34","key":"10.1053\/j.seminhematol.2021.02.005_bib0061","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter Phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.005_bib0062","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.005_bib0063","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12185-019-02675-1","article-title":"Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia\/lymphoma after haploidentical stem cell transplantation","volume":"110","author":"Morishige","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0064","first-page":"21","article-title":"Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy","volume":"11","author":"Oka","year":"2019","journal-title":"Leuk Res Rep"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/CAD.0000000000000895","article-title":"Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia","volume":"31","author":"Oka","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"36","key":"10.1053\/j.seminhematol.2021.02.005_bib0066","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1200\/JCO.2010.32.1380","article-title":"Is Zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma?","volume":"28","author":"Ishitsuka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0067","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1346-8138.2012.01639.x","article-title":"Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group","volume":"40","author":"Sugaya","year":"2013","journal-title":"J Dermatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0068","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1346-8138.12374","article-title":"Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma","volume":"41","author":"Tsukasaki","year":"2014","journal-title":"J Dermatol"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.02.005_bib0069","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.005_bib0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1535-6108(02)00187-3","article-title":"The EZH2 polycomb transcriptional repressor\u2013a marker or mover of metastatic prostate cancer?","volume":"2","author":"Sellers","year":"2002","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.005_bib0071","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nature genetics"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.005_bib0072","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.005_bib0073","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.005_bib0074","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","article-title":"Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity","volume":"22","author":"Kreitman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.005_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","article-title":"Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.005_bib0076","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/cas.12735","article-title":"A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma","volume":"106","author":"Ishitsuka","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2021.02.005_bib0077","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.005_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135042","article-title":"The impact of opportunistic infections on clinical outcome and healthcare resource uses for adult T cell leukaemia","volume":"10","author":"Maeda","year":"2015","journal-title":"PLoS One"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:16Z","timestamp":1758522496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000159"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of adult T-cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}